Prime Medicine Surges as Wilson Disease Trial Enters Human Testing

The clinical trial is an open-label, global study assessing the safety and preliminary efficacy of PM577a in adults and adolescents carrying at least one p.H1069Q mutation in the ATP7B gene. Initial enrollment focuses on adult patients already stabilized on standard-of-care treatments. Beyond the trial’s start, the company secured a rare pediatric disease designation from the FDA for the investigational therapy. This regulatory nod and the successful initiation of dosing signal a significant advancement for Prime Medicine’s pipeline, particularly as the biotechnology firm shifts from preclinical development to active human testing.